Clinical Trial Update: Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of buparlisib (BKM120) in patients with recurrent/refractory primary central nervous system lymphoma and recurrent/refractory secondary C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Buparlisib (BKM120) (buparlisib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma, Primary Central Nervous System Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-10-19